Gamma Medica, a Salem, NH-based developer of advanced digital molecular imaging technologies, raised $11.5m in financing.
It included $6.5m in growth capital financing facility from specialty finance company Hercules Technology Growth Capital (NYSE: HTGC) and $5.0m from existing investor Psilos Group.
The company intends to use the funds to increase sales and marketing efforts and grow adoption of Molecular Breast Imaging (MBI) on a global scale.
Led by Jim Calandra, President and CEO, Gamma Medica develops advanced digital imaging technologies for the early detection of breast cancer. The company’s LumaGEM® Digital MBI system is a commercially available, dual head, fully solid-state digital imaging system utilizing cadmium zinc telluride (CZT) technology for molecular breast imaging.
It is currently in use at premier hospitals and breast centers throughout the U.S.